Trial to Reduce Cardiovascular Events with Aranesp Therapy.

Trial Profile

Trial to Reduce Cardiovascular Events with Aranesp Therapy.

Phase of Trial: Phase III

Latest Information Update: 16 Jun 2017

At a glance

  • Drugs Darbepoetin alfa (Primary)
  • Indications Anaemia
  • Focus Adverse reactions; Registrational
  • Acronyms TREAT
  • Sponsors Amgen
  • Most Recent Events

    • 01 Oct 2015 Pooled analysis of 2 studies of total 4854 patients including patients from this TREAT trial and other RED-HF trial [see CTP 700244591] were published in the European Journal of Heart Failure.
    • 05 Nov 2010 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top